Everything between your registration certificate and your first purchase order: pricing, importation, stock, distribution, and channel listing, run as one programme under our own licences.
A registration certificate lets your product into the UAE. It does not put the product on a shelf, on a formulary, or on a purchase order. Market access is everything between the certificate and that first order: pricing, importation, stock, distribution, and channel listing.
Most manufacturers discover this gap after approval, when the momentum is gone. Our market access practice in the UAE exists to close it. We treat pharmaceutical market access and drug commercialization in the UAE as one programme with regulatory dependencies, not two separate projects, and we set the market entry strategy before the dossier is filed.
Five stages, one accountable team, with the licences already in place at every step that needs them.
EDE product classification where the category is unclear, and the registration route and market entry strategy that follow from it.
Manufacturer site registration and product registration through to certificate issuance, each valid for five years.
The pricing and reimbursement submission under the authority pricing framework, managed through to an approved price.
First shipments brought in under our own importer licence and received into our GDP medical warehouse.
Distributor onboarding, then retail, hospital, and tender listing to open every channel that matters for the product.
Reports written for HQ decision making, not for the shelf.
Who is registered, who is listed where, and where the openings sit in your therapeutic area.
Benchmarks across comparable registered products to frame your pricing and reimbursement position in the UAE.
Market sizing built from UAE data, so volume forecasts rest on evidence rather than assumption.
The current EDE landscape mapped to your portfolio: pathways, timelines, and risks for HQ decision making.
Before any launch is funded, HQ wants numbers it can defend. We build the business case with you: market sizing, price corridors, and launch timelines, grounded in UAE data and our own submission experience rather than optimism.
Manufacturers use us for market access consulting in Dubai because the plan we present is the plan we then execute. The business case, the pricing submission, and the launch programme come from the same team, so the numbers HQ approves are the numbers the launch runs on.
Advice does not import stock. Under the UAE pharmaceutical law in force from 2025, only entities holding a pharmaceutical facility or medical warehouse licence with the corresponding EDE import permit may import pharmaceuticals and medical devices. We hold those licences ourselves.
As your Local Representative and Marketing Authorisation Holder (MAH), we also hold your registration. Our warehouse receives the stock. Our importer licence brings it in. The loop from approval to first order closes inside one company, on one timeline, with one accountable team.
We act as your UAE Local Representative and Marketing Authorisation Holder, so the registration stays independent.
Importation under our own licensed facility, medical warehouse, and EDE import permits.
Shortlisting, due diligence, and onboarding of the right UAE distributor for your portfolio.
The single biggest reason products fail in the UAE is not registration, it is the wrong distribution partner. Pharmareg maintains a large, established network of distributors across the UAE, spanning pharmacy chains, hospitals and institutional buyers, retail, and online marketplaces. We do not hand you a list: we match your product to the distributors who already perform in your category, negotiate the commercial terms, arrange the authorisation letters against your registrations, and execute the distribution agreements, so your product moves from certificate to shelf with a partner who is accountable.
Active distributor relationships across pharmacy, hospital, retail, and online channels.
Distributors selected on proven performance in your product category, not availability.
Commercial terms, authorisation letters, and distribution agreements negotiated and executed by us.
Onboarding does not end at the agreement, we stay in the loop through launch and the first orders.
Send us the product details and we will come back with a roadmap, classification opinion, and indicative timeline within 48 hours.
Talk to our regulatory team